Johnson & Johnson Stock price

Equities

JNJ

US4781601046

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-02-09 pm EST 5-day change 1st Jan Change
156.8 USD +0.23% Intraday chart for Johnson & Johnson +0.10% +0.01%
Sales 2023 85.16B Sales 2024 * 88.44B Capitalization 377B
Net income 2023 13.33B Net income 2024 * 20.94B EV / Sales 2023 4.43 x
Net Debt 2023 * 5.63B Net cash position 2024 * 14.08B EV / Sales 2024 * 4.11 x
P/E ratio 2023
30.1 x
P/E ratio 2024 *
17.6 x
Employees 152,700
Yield 2023 *
2.93%
Yield 2024 *
3.12%
Free-Float 77.07%
More Fundamentals * Assessed data
Dynamic Chart
1 day+0.23%
1 week+0.10%
Current month-1.35%
1 month-3.16%
3 months+6.46%
6 months-8.95%
Current year+0.01%
More quotes
1 week
155.31
Extreme 155.31
159.37
1 month
155.31
Extreme 155.31
163.58
Current year
155.31
Extreme 155.31
163.58
1 year
144.95
Extreme 144.95
175.97
3 years
144.95
Extreme 144.95
186.69
5 years
109.16
Extreme 109.16
186.69
10 years
81.79
Extreme 81.79
186.69
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 88-12-31
Director of Finance/CFO 57 97-12-31
Director of Finance/CFO - 09-04-30
Members of the board TitleAgeSince
Director/Board Member 71 19-04-24
Director/Board Member 72 14-06-18
Director/Board Member 70 09-10-21
More insiders
Date Price Change Volume
24-02-09 156.8 +0.23% 6,529,202
24-02-08 156.4 -1.00% 9,754,960
24-02-07 158 -0.05% 8,690,294
24-02-06 158.1 +1.45% 9,230,611
24-02-05 155.8 -0.52% 9,121,808

Delayed Quote Nyse, February 09, 2024 at 04:00 pm EST

More quotes
Johnson & Johnson is one of the world's leading producers of healthcare products. Net sales break down by family of products as follows: - pharmaceutical products (55.4%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.; - medical products and equipment (28.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals; - consumer health products (15.7%): OTC drugs (Tylenol, Sudafed, Benadryl, Zyrtec, Motrin, Nicorette and other brands), health and beauty products (Aveeno, Clean & Clear, Dr. CI:Labo, Neutrogena and OGX), baby care products (Johnson's and Aveeno Baby), oral care products (Listerine), feminine hygiene products (Stayfree and Carefree and o.b.), wound care products (Band-Aid and Neosporin) etc. At the end of 2022, Johnson & Johnson has 89 manufacturing facilities located in the United States (28), North America (9), Europe (27), Africa and Asia/Pacific (25). Net sales are distributed geographically as follows: the United States (51.2%), Europe (24.7%), Asia/Pacific and Africa (17.7%) and other (6.4%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
156.8 USD
Average target price
174.5 USD
Spread / Average Target
+11.35%
Consensus
1st Jan change Capi.
+0.01% 377 B $
+26.97% 666 B $
+19.17% 536 B $
+15.07% 318 B $
+12.33% 307 B $
-8.02% 207 B $
+4.05% 206 B $
-7.92% 191 B $
-4.27% 156 B $
-3.63% 117 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Johnson & Johnson - Nyse
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer